Clinical Observation on Shexiang Baoxin Pil and Metoprolol,Trimetazidine in the Treatment of Coronary Heart Disease with Related Heart Failure
Yao Chaoyang
Abstract：Objective To observe the clinical effect of Shexiang Baoxin pil (SXBXP)and metoprolol,trimetazidine in the treatment of coronary heart disease(CHD)with heart failure(HF).Methods One hundred and four patients with CHD related HF from May 2014 to June 2015 were randomly divided into two groups:control group(n=52)treated with routine treatment plus metoprolol,trimetazi-dine,and treatment group(n=52)treated with routine treatment plus metoprolol,trimetazidine,SXBXP.The clinical treatment,heart function and adverse reactions were observed.The quality of life(QOL)in admission and discharge patients were assessed by 36 I-tem Short Form Health Survey (SF 36)before and after treatment.Results The total effective rate was 98.08% in treatment group, which was higher than that in control group(84.62%,P<0.05).The team overal adverse reaction rate was 1.92% in treatment group,which was higher than that in control group(13.46%,P<0.05).After treatment,the cardiac function and SF 36 scores were improved in two groups(P<0.05).The cardiac function level and SF 36 scores were significantly better than that in control group (P<0.05).Conclusion SXBXP plus metoprolol and trimetazidine can improve the cardiac function and the treatment effect,reduce adverse reactions,improve quality of life in patients with CHD related HF.
Keywords：coronary heart disease with heart failureShexiang Baoxin pilmetoprololtrimetazidinecardiac function
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 615-617 )